Back to Results

A double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus.

Study category: Diabetes & Hormone Disorders

Is this Study for You?

Let's Get Started!

Details
Age

Child

Phase

III - Research Studies that gather more information about a drug's safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Petter Bjornstad

Petter Bjornstad

Study ID

Protocol Number: 18-1223

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers